Invasive Meningococcal Disease: Epidemiology and Prevention
Epidemiology, clinical manifestations and prevention strategies for invasive meningococcal disease in South Africa.
Science in Meningitis
Meningococcal Vaccination Impact: Hajj Pilgrimage Case Studies and Global Benefits
Comprehensive analysis of meningococcal vaccine effectiveness during Hajj pilgrimages, featuring case studies from Singapore and Saudi Arabia. Highlights significant reduction in IMD cases post-vaccination and explores the broader benefits of meningococcal conjugate vaccines, including herd immunity and reduced global transmission.
Beyond Survival: Why Does IMD Rank as a High-Impact, Low-Incidence Threat Among Other Vaccine-Preventable Diseases?"
Comprehensive analysis of Invasive Meningococcal Disease (IMD) outcomes, featuring detailed mortality rates by serogroup and age group, with focus on the 20% survivor sequelae rate. Includes comparative analysis with other vaccine-preventable diseases (VPDs) and highlights the critical 24-hour window for treatment intervention.
Protecting Pilgrims: Meningococcal Disease Risk Factors During Mass Gatherings
Comprehensive analysis of meningococcal disease risk factors during mass religious gatherings, with focus on the Hajj pilgrimage. Details environmental challenges, demographic vulnerabilities, and transmission dynamics among pilgrims, local residents, and healthcare workers in Mecca, with emphasis on crowded conditions and N. meningitidis carriage rates.
Age and Serogroup Patterns: IMD in South Africa
Comprehensive analysis of Invasive Meningococcal Disease (IMD) patterns in South Africa, featuring GERMS-SA surveillance data from 2018-2024. Highlights age-specific incidence rates, with detailed focus on infant vulnerability (1.6 per 100,000) and adolescent/young adult peaks. Includes serogroup distribution trends across the country.
Age-Related Risk Factors for IMD: From Infants to Elderly
Comprehensive overview of age-specific risk factors for Invasive Meningococcal Disease (IMD), detailing vulnerability patterns across different life stages. Features specific risks for infants, adolescents, and elderly populations, including the impact of maternal antibody decline, nasopharyngeal colonization, and immunosenescence in older adults.
.2023-12-04-08-14-49.svg)
The Biology and Transmission of Neisseria Meningitidis
Biology and transmission dynamics of Neisseria meningitidis relevant to disease risk and prevention strategy.
Recognising the Clinical Manifestations of Meningococcal Disease
The evolving clinical presentation of invasive meningococcal disease, from early subtle signs to severe features.
National surveillance data indicates that invasive meningococcal disease incidence has fluctuated in recent years, with an increasing trend observed since 2021 following historically low pandemic-era levels. Serogroups B and W predominate in South African cases, followed by C and Y. Infants consistently show the highest age-specific incidence, with a secondary peak typically seen in adolescents and young adults. This local pattern informs which prevention strategies are most relevant to South African practice.
Invasive meningococcal disease can progress from initial non-specific symptoms, such as fever and irritability, to severe sepsis or meningitis within as little as 24 hours in some cases. This rapid progression reflects the organism's ability to invade the bloodstream and central nervous system efficiently once initial colonisation occurs. Early recognition of subtle warning signs is therefore critical to timely treatment and improved outcomes. This urgency underscores the importance of maintaining clinical suspicion even with non-specific initial presentations.
South Africa has both polysaccharide and conjugate quadrivalent vaccines available, targeting serogroups A, C, W and Y, with the conjugate vaccine suitable from nine months of age. Vaccination against serogroup B, which remains a leading cause of disease locally, may require separate consideration depending on product availability and clinical context. Vaccination decisions should consider individual risk factors, such as age, immunocompromise or anticipated exposure. Current national guidance should be consulted for specific vaccination recommendations.
Confirm that you are a healthcare professional to continue reading.
Click login to continue